文献速递瓣膜病与结构性心脏病冠心病

经导管主动脉瓣置换术后外科取出术的发生率、特征、预测因素与结局

Incidence, Characteristics, Predictors, and Outcomes of Surgical Explantation After Transcatheter Aortic Valve Replacement.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

基于美国Medicare数据库2012—2017年132,633例TAVR患者,外科取出术发生率为0.2%(227例),早期与近期TAVR时代分别为0.28%与0.14%。取出主要原因为生物瓣衰败(79.3%),术后30天与1年死亡率分别为13.2%与22.9%,取出组死亡风险显著高于未取出组(HR 4.03,95%CI 1.81–8.98)。

要点

  • TAVR后外科取出术总体发生率低(0.2%),但30天死亡率达13.2%。
  • 取出主要因生物瓣衰败(79.3%),中位时间为212天。
  • 取出组死亡风险显著升高(HR 4.03,95%CI 1.81–8.98)。

核心结论

  • TAVR外科取出术总体发生率低,但短期死亡率高。
  • 取出组死亡风险显著高于未取出组,风险比4.03(95%CI 1.81–8.98)。
  • 提示需开展TAVR取出机制的深入研究,并关注主动脉瓣狭窄的终身管理,尤其是年轻患者。

研究设计与样本

  • 基于Medicare Provider数据库的全国代表性人群回顾性分析。
  • 纳入2012—2017年全部接受TAVR的美国患者,共132,633例。
  • 取出时间自TAVR出院起算,采用时间依赖Cox比例风险回归与 landmark 分析评估术后生存。

主要发现

  • 外科取出术发生率为0.2%(227/132,633),早期与近期TAVR时代分别为0.28%与0.14%。
  • 取出中位时间212天,8.8%在30天内、70.9%在1年内完成取出。
  • 主要再干预指征为生物瓣衰败(79.3%)。
  • 取出组较未取出组更年轻(平均73.7岁 vs. 81.7岁),心衰比例更低(55.9% vs. 65.8%),低危比例更高(15% vs. 2.4%),均p<0.05。
  • 30天与1年死亡率分别为13.2%与22.9%,不随取出时间、TAVR时代或是否合并感染性心内膜炎而变化(均p>0.05)。

关键数值与推荐

  • 外科取出术发生率0.2%(227/132,633例)。
  • 取出中位时间212天;30天内取出8.8%,1年内取出70.9%。
  • 主要指征为生物瓣衰败,占79.3%。
  • 30天死亡率13.2%,1年死亡率22.9%。
  • 时间依赖Cox回归:取出组死亡风险比4.03(95%CI 1.81–8.98)。

临床怎么用

  • TAVR术后需警惕生物瓣衰败导致的外科取出风险,短期死亡率较高。
  • 对年轻、低危TAVR患者应重视终身瓣膜管理策略的规划。
  • 取出指征、时机与外科取出年份未显示与更差生存相关,但需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently, there is a paucity of information on surgical explantation after transcatheter aortic valve replacement (TAVR). OBJECTIVES: The purpose of this study was to examine the incidence, patient characteristics, predictors, and outcomes of surgical explantation after TAVR using a population-based, nationally representative database. METHODS: We analyzed the Medicare Provider profile to include all U.S. patients undergoing TAVR from 2012 to 2017. Time to surgical explant was calculated from the index TAVR discharge to surgical explantation. Post-operative survival was assessed using time-dependent Cox proportional hazard regression analysis and landmark analysis. RESULTS: The incidence of surgical explantation was 0.2% (227 of 132,633 patients), and was 0.28% and 0.14% in the early and newer TAVR era, respectively. The median time to surgical explant was 212 days, whereas 8.8% and 70.9% underwent surgical explantation within 30 days and 1 year, respectively. The primary indication for reintervention was bioprosthetic failure (79.3%). Compared with the no-explant cohort, the explant cohort was significantly younger (mean age 73.7 years vs. 81.7 years), with a lower prevalence of heart failure (55.9% vs. 65.8%) but more likely a lower-risk profile cohort (15% vs. 2.4%; all p < 0.05). The 30-day and 1-year mortality rates were 13.2% and 22.9%, respectively, and did not vary by either time to surgical explant or TAVR era, or between patients with versus without endocarditis (all p > 0.05). The time-dependent Cox regression analysis demonstrated a higher mortality in those with surgical explantation (hazard ratio: 4.03 vs. no-explant group; 95% confidence interval: 1.81 to 8.98). Indication, time-to-surgical-explant, and year of surgical explantation were not associated with worse post-explantation survival (all p > 0.05). CONCLUSIONS: The present study provides updated evidence on the incidence, timing, and outcomes of surgical explantation of a TAVR prosthesis. Although the overall incidence was low, short-term mortality was high. These findings stress the importance of future mechanistic studies on TAVR explantation and may have implications on lifetime management of aortic stenosis, particularly in younger patients.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Hirji SA, Percy ED, McGurk S, et al. Incidence, Characteristics, Predictors, and Outcomes of Surgical Explantation After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2020. PMID: 33059830. doi:10.1016/j.jacc.2020.08.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。